High SVR12 With 8-Week Course of Direct-Acting Antivirals in Adolescents and Children With Chronic Hepatitis C: A Comprehensive Analysis

Zuqiang Fu1,2†, Chen Dong3†, Zhijun Ge4, Chunhui Wang2, Yun Zhang1,2, Chao Shen1,2, Jun Li5, Chuanlong Zhu6, Yan Wang7, Peng Huang1,2* and Ming Yue5*

1 Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China, 2 Eastern Theater Command Centers for Disease Control and Prevention, Institute of Epidemiology and Microbiology, Nanjing, China, 3 Department of Epidemiology and Statistics, School of Public Health, Medical College of Soochow University, Suzhou, China, 4 Department of Critical Care Medicine, The Affiliated Yixing Hospital of Jiangsu University, Yixing, China, 5 Department of Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Direct-acting antiviral (DAA) treatment for 8 weeks has a sustained virological response rate in adults with chronic hepatitis C. We have conducted a systematic review and meta-analysis to compare the efficacy and safety of the 8-week vs. 12/24-week DAA treatment in adolescents and children with CHC. The PubMed, Web of Science, and Cochrane databases were searched for the relevant articles from January 1, 2017 to August 28, 2020 and further screened for literature reviews on April 1, 2021. Pool proportions with 95% CIs for SVR12 were summarized with fixed/random effects models using Freeman–Tukey double arcsine transformation. Subgroup analysis was used to explore the source of heterogeneity. Thirty-six relevant publications were identified. For adolescents aged 12–17 years old, the pooled SVR12 and AE rate were 99.4% (95% CI: 98.7–99.9) and 34.7% (95% CI: 31.9–37.6). No one discontinued treatment due to drug intolerance. In addition, the SVR12 adolescents treated for 12 and 8/24 weeks were 99.3% (95% CI: 98.4–99.9) and 100%, respectively. The pooled SVR12 rate, AEs, and SAEs for children younger than 12 years were 98.9% (95% CI: 97.3–99.8), 51.6% (95% CI: 47.0–56.2), and 1.1% (95% CI: 0.4–2.5), respectively. The most common AE was fatigue (28.4%). The SVR12 was 98.8% (95% CI: 97.1–99.8) and 100% for the pediatric patients treated for 12 weeks and 8/24 weeks, respectively. Taken together, DAA are generally effective against CHC and well-tolerated by the adolescents and children. A treatment duration of 8 weeks is equally effective and safe as 12/24 weeks in this demographic group.

Keywords: hepatitis C virus, direct-acting antivirals regimens, adolescents and children, sustained virological response, treatment duration
**INTRODUCTION**

Hepatitis C is caused by hepatitis C virus (HCV) infection and afflicted 71.7 million people or 1% of the global population in 2015 (1, 2), of which 13.2 (11.5–21.2) million were children and adolescents aged 1–15 years (3). Only 1.76 million (13%) of the patients received treatment, and 86% (1.51 million) were treated with direct-acting antivirals (DAAs) (1, 2).

Vertical HCV infection is cleared spontaneously without treatment in 20% of the pediatric patients, while the remaining 80% develop chronic infection in the first 4 years of life that usually persists into adulthood (4–6). Early diagnosis and treatment at younger age can reduce the prevalence of chronic infection in adulthood, and therefore reduce the global burden of HCV (7). However, although 5.5 million people with chronic HCV have been treated so far, most of these patients are adults that received the less effective interferon-based regimens (2).

The Food and Drug Administration (FDA) approved supplemental administration of sofosbuvir (SOF) and a combination of sofosbuvir and ledipasvir (SOF+LDV) in April 2017 to treat HCV in adolescents aged 12–17 years (8). In addition, several single-arm clinical trials conducted in the last 2 years have shown that DAAs are highly effective in pediatric CHC patients aged 6–12 years (9, 10). However, most of these studies have only analyzed the efficacy of DAAs on specific pediatric patient populations, such as those infected with HCV genotype 4 (GT) (11, 12), or the treatment experienced (TE) or treatment-naïve (TN) patients (13). The efficacy of short-duration (8 weeks) DAA treatment in adolescents and children with HCV infection has not been summarized so far.

The aim of this study was to comprehensively evaluate the efficacy and safety of 8-week vs. 12/24-week DAA regimens in adolescents and children with HCV infection using data from published studies. Our findings provide valuable information for medical professionals and researchers.

**MATERIALS AND METHODS**

This systematic review and meta-analysis was conducted according to the preferred reporting items for systematic review and meta-analyses (PRISMA) statement (Supplementary Table 1) (14).

**Literature Search**

PubMed, Cochrane Library, and Web of Science databases were searched for the relevant articles from January 1, 2017 to August 28, 2020. Literature reviews were searched on April 1, 2021. There were no restrictions on the year of publication and language. To avoid missing any study, several keywords were replaced with their synonyms. The following search terms were applied: “hepatitis C virus” (e.g., “HCV”; “CHC”; “hepatitis c”); “direct-acting antiviral” (e.g., “DAA”; “Sofosbuvir”; “Dasabuvir”; “Daclatasvir”; “Ledipasvir”; “Ombitasvir”; “Elbasvir”; “Velpatasvir”; “Boceprevir”; “Telaprevir”; “Simeprevir”; “Asunaprevir”; “Paritaprevir”; “Grazoprevir”); “pediatric” (e.g., “paediatric”; “pediatr”); and “children” (e.g., “child”; “teenager”; “kid”; “adolescent”; “youngster”; “juvenile”) (Supplementary Table 2). All types of studies were collated initially. The procedure is outlined in Figure 1.

**Inclusion and Exclusion Criteria**

Studies that met the following criteria were included: (i) HCV infection (HCV RNA positive in blood) (8), (ii) adolescents (12–17 years) or pediatric (<12 years of age) patients, (iii) DAA treatment regimen, (iv) all HCV genotypes, (v) definite outcome variables (SVR12), (vi) TN or TE patients, and (vii) informed consent.

The exclusion criteria of the studies were as follows: (i) co-infection with HBV or HIV, (ii) evidence of HCC or other malignancy, (iii) history of solid organ or bone marrow transplantation, (iv) decompensated liver disease or chronic liver disease of a non-HCV etiology, (v) review, case report, or articles with >10 subjects, and (vi) not treated with any DAA-containing regimens.

**Study Selection**

The duplicate studies were first eliminated using Endnote software, and the unrelated studies were excluded by browsing through the titles and abstracts. Studies with only adult subjects or lacking DAAs in the treatment regimens were excluded, and those reporting on the efficacy or safety of DAA treatment in children were retained. The bibliographies of the most recent relevant literature reviews were manually inspected to obtain additional articles. To avoid selection bias caused by one person, two reviewers (Mr. Fu and Miss Yue) evaluated all abstracts and selected the relevant studies for full-text reading. Any disagreement was resolved by consensus among all authors.

**Research Outcomes**

The primary outcome was the efficacy of DAA regimens in adolescents and children, which was defined as the percentage of patients with SVR12 [HCV RNA < the lower limit of quantitation (LLOQ) at 12 weeks after cessation of therapy]. The SVR12 in this meta-analysis was the intention-to-treat (ITT) SVR12. The second outcome was the percentage of patients with adverse events (AEs) and serious AEs (SAEs). The AEs were defined as any unfavorable medical event reported by patients or any aberrations observed by the clinicians from the baseline laboratory indices after administration of the first dose until 30 days after the last dose. Common AEs included fatigue, nausea, and so on. The SAEs were defined as any event causing disability, congenital malformation, or death (8, 15–17). The worsening of laboratory test values from baseline was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (18). The safety of DAA regimen for HCV-infected patients was evaluated by the rate of drug-related AEs, SAEs, discontinuation, and laboratory abnormalities (19).

**Data Extraction and Quality Evaluation**

All relevant data including SVR12 (the primary endpoints of interest), side effects, study characteristics (e.g., study author, publication date, study type, and study sites), patient characteristics at baseline (e.g., age, sex rate, genotype, and...
FIGURE 1 | Preferred reporting items for the review flow diagram for identification of relevant studies.
treatment regimen/duration), and possible factors that affect the outcomes of treatment were extracted from the articles. The study subjects were divided into the adolescents (12–17 years) and children (<12 years of age) groups.

All studies were assessed for methodological quality using the tool of Review Manager 5.2. The items of evaluation refer to a National Institutes of Health quality assessment tool: the tool for “Before-After (Pre-Post) Studies With No Control Group” (https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools) (Supplementary Table 3). Each criterion was graded as “yes,” “no,” or “unclear,” which corresponded to “low bias risk,” “high bias risk,” and “unclear risk of bias,” respectively.

Statistical Analyses

R x64-3.6.1 software (The R Foundation for Statistical Computing) was used for the meta-analysis. Pool proportions with 95% CIs for SVR were summarized with fixed effects models using Freeman–Tukey double arc sine transformation (20). Fixed/random effects models were used in all analyses, and statistical heterogeneity was calculated with the $I^2$ method and subgroup differences using the Q-test. $I^2$ was calculated as follows: $I^2 (\%) = 100 \times (Q - df)/Q$, where Q is Cochrane's heterogeneity statistic and df indicates the degree of freedom. Negative values for $I^2$ were set to zero, and an $I^2 \geq 50\%$ was considered to have substantial heterogeneity. Publication bias was analyzed by Funnel plots. $P < 0.05$ was considered statistically significant.

RESULTS

A total of 741, 1,344, and 188 studies were initially identified in the PubMed, Web of Science, and Cochrane Library databases, respectively, of which 444 duplicate articles were excluded. After screening the titles and abstracts, 1,767 articles were further excluded. After including 21 additional articles from manual search of the reference lists, a total of 73 papers were eligible for full-text screening, of which 45 were excluded for incomplete data and/or inappropriate age groups (patients aged ≥18 years) and 7 for patients with co-morbidities. Another eight articles were included after the later literature search. Finally, 36 articles were included for further review, except for one that included both children and adolescents (Figure 1).

Studies and Patients’ Characteristics

The main characteristics of the patients and studies are summarized in Table 1. A total of 28 studies were included, of which 18 were from Egypt, 7 from the United States, 4 from India, and 5 from multiple or other countries. All studies were observational, and 14 were multi-center studies. Except for three studies that did not specify the age groups, a total of 1,718 patients (1,253 adolescents and 465 children) were included in the studies, of which 792 were infected with HCV GT4, 545 with HCV GT1, 156 with GT3, 43 with HCV GT2, 1 with HCV GT5, and 213 with unknown GTs. Apart from 267 patients with unavailable treatment history, 1,216 were TN and 272 were TE. The majority of the patients (59%, 951/1,612) were males.

The methodological quality of each study is shown in Supplementary Figures 1, 2. The quality assessment criteria according to the National Institute of Health quality assessment tools are listed in Supplementary Table 3 (https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools). As shown in Supplementary Figure 2, most items had good level of research quality except for Q5, which was the result of patient specificity.

Efficacy Analysis of DAAs in Adolescents With CHC

A total of 24 studies including 1,253 adolescents patients were included for evaluating SVR12. The fixed-effect model showed that the pooled SVR12 rate was 99.4% (837/1,253, 95% CI: 98.7–99.9) (12, 15, 16, 18, 22, 23, 27–32, 34–36, 38, 39, 42–48). There was no significant heterogeneity ($I^2 = 0\%$, $P = 0.83$) (Figure 2A) or publication bias ($t = 0.22, P = 0.828$) (Supplementary Figure 3A) among these studies. There were three different treatment cycles of 8, 12, and 24 weeks. As shown in Table 2, the SVR12 rate was 100% (193/194, 95% CI: 98.7–100) for patients treated for 8 weeks, 99.3% (998/1,015, 95% CI: 98.4–99.9) for those treated for 12 weeks, and 100% (43/44, 95% CI: 98.9–100) for those treated for 24 weeks. The pooled SVR12 rate was 100% (95% CI: 100.0–100.0) (Supplementary Figure 4A), with little heterogeneity among the three groups ($P = 0.398$). In addition, there were no significant differences in the pooled SVR12 rates when analyzed for the genotype, treatment history, and treatment regimen subgroups (Supplementary Figures 6A–8A).

Safety Analysis of DAAs in Adolescents With CHC

As shown in Table 3 and Supplementary Figure 5A, the AE rate was 31, 36.1, and 41.7% among adolescents treated with DAAs for 8, 12, and 24 weeks, respectively. No significant heterogeneity was observed among three groups (31.0 vs. 36.1 vs. 41.7%, $P = 0.918$). Furthermore, the pooled AE rate for the adolescents aged 12–17 years was 34.7% (435/1,109, 95% CI: 31.9–37.6) and the SAE rate was 0.2% (95% CI: 0–0.6). The top AEs in adolescents were headache (22.6%, 206/910), abdominal pain (21.1%, 118/560), fatigue (15.5%, 129/832), nausea (15.4%, 90/585), and diarrhea (15.0%, 104/695).

Efficacy Analysis of DAAs in Children With CHC

A total of nine studies including 465 pediatric patients were included for SVR12 evaluation, and the fixed-effect model showed that the pooled SVR12 rate was 98.9% (454/465, 95% CI: 97.3–99.8) (10, 11, 13, 17, 21, 24–26, 37, 46). There was little heterogeneity among these studies ($I^2 = 35\%$, $P = 0.13$) (Figure 2B), and no significant publication bias was observed as per the funnel plot ($t = -0.68, P = 0.519$) (Supplementary Figure 3B). Eight of these studies reported the efficacy of 12-week treatment, two studies reported the efficacy of 8-week treatment, and only one study observed the outcomes
### TABLE 1 | Main characteristics of the studies and patients included in this review.

| References          | Study design         | Study sites                        | Genotype (n)          | Treatment history (TN/TE) | Man (n, %) | Age (median) | Treatment regimen | Treatment duration (weeks) | Total (%) | Primary events, SVR (%) |
|---------------------|----------------------|------------------------------------|-----------------------|---------------------------|------------|--------------|-------------------|---------------------------|------------|-------------------------|
| Rosenthal et al. (21)** | Multicenter, open-label | USA G1 (26) | 26/0 | 9 (35) | 7.5 (3.0–11.0) | OBV/PTV/R + DSV+RBV | SOF+LDV | 12 | 26 | SVR12, 96.0 (25/26) |
| Fouad et al. (22) | Single-arm | Egypt NA | 36/8 | 28 (60.9) | 13.5 (12–17) | SOF+LDV | 12 | 46 | SVR12, 100.0 (46/46) |
| Mehlouf et al. (23) | Open-label | Egypt G4 (50) | 6/44 | 36 (72.0) | 13.6 (12–17) | SOF+LDV | 12 | 50 | SVR12, 100.0 (50/50) |
| Jonas et al. (15) | Open-label | USA G1 (37), G2 (3), G3 (1), G4 (3) | 36/8 | 21 (47.7) | 14 (12–17) | G+P | 8 | 44 | SVR12, 100.0 (44/44) |
| Behairy et al. (13) | Single-arm | Egypt G4 (30) | 30/0 | 20 (66.7) | 6.7 (4–10) | SOF+LDV | 8 | 30 | SVR12, 100.0 (30/30) |
| Schwarz et al. (24) | Multicenter, open-label | USA, UK, and Australia G1 (33), G4 (1) | 33/1 | 24 (71.0) | 5 (3–6) | SOF+LDV | 12 | 34 | SVR12, 97.1 (33/34) |
| Kamal et al. (25) | Multicenter | Egypt G4 | 22/0 | 19 (86.0) | 4.8 (3–6) | SOF+LDV | 8;12 | 22 | SVR12, 100.0 (22/22) |
| Rosenthal et al. (26)** | Multicenter, open-label | USA G2 (18), G3 (36) | 53/1 | 14 (25.9) | 6.5 (3–11) | SOF+RBV | 12 | 54 | SVR12, 98.2 (54/54) |
| Serranti et al. (27) | Multicenter, open-label | Italian G1 (14) | 14/10 | 6 (42.9) | 16.5 (12–27) | SOF+LDV | 8 | 14 | SVR12, 100.0 (14/14) |
| Dhiman et al. (28) | Multicenter, open-label | India G1 (9), G3 (24), G4 (2), G5 (1), unknown (21) | 57/0 | 40 (69.3) | 15.8 (12–17) | SOF+LDV; SOF+DCV ± RBV | 12;24 | 57 | SVR12, 98.3 (57/57) |
| Abdel Ghaffar et al. (29) | Open-label | Egypt G4 (40) | 40/0 | 25 (62.5) | 12.27 (8–17.58)* | SOF+DCV | 12 | 40 | SVR12, 97.5 (39/40) |
| Fouad et al. (30) | Observational | Egypt G4a (51) | 35/16 | 32 (62.7) | 14.7 (11–17.5) | SOF+LDV | 12 | 51 | SVR12, 100.0 (51/51) |
| El-Khayat et al. (15) | Cross-sectional | Egypt G4 (157) | 69/94 | 97 (62.0) | 14 (12–17) | SOF+LDV | 8;12 | 157 | SVR12, 98.1 (157/157) |
| Nagral et al. (31) | Single-arm | India G1 (12), G3 (5), unknown (1) | 17/1 | 9 (50.0) | 15.1 (12–17) | SOF+LDV; SOF+DCV ± RBV | 12;24 | 18 | SVR12, 88.9 (16/18) |
| El-Araby et al. (11) | Observational | Egypt G4 | 80/20 | 66 (66.0) | 13.8 (9–12) | SOF+LDV | 12 | 100 | SVR12, 100.0 (100/100) |
| Padhi (10) | Observational | India G3 (14) | 14/0 | 12 (85.7) | 9.5 (7–13) | SOF+DCV | 12 | 14 | SVR12, 100.0 (14/14) |
| Mehta et al. (32) | Observational | India G3 (10) | 10/0 | 10 (100) | 13 (11–17) | SOF+DCV | 12 | 10 | SVR12, 100.0 (10/10) |
| Alkaiby et al. (33) | Observational | Iraq G1 (10), G4 (2), unknown (10) | 15/7 | 14 (63.6) | 12.5 (7–17)* | SOF+LDV | 12 | 22 | SVR12, 90.9 (22/22) |
| El-Karakey et al. (34) | Observational | Egypt G4 (40) | 30/10 | 26 (65.0) | 13.9 (11.5–17.5) | SOF+LDV | 12 | 40 | SVR12, 100.0 (40/40) |
| Yakoot et al. (35) | Multicenter, open-label | Egypt G4 (30) | NA | 17 (56.7) | 12.567 (12–17) | SOF+DCV | 12 | 30 | SVR12, 96.7 (29/30) |
| Murray et al. (17) | Multicenter, open-label | USA G1 (88), G3 (2), G4 (2) | 72/20 | 84 (91.5) | 9 (6–11) | SOF+LDV ± RBV | 12;24 | 92 | SVR12, 98.9 (92/92) |
| Leung et al. (36) | Multicenter, open-label | USA G1 (31), G4 (7) | 25/13 | 13 (34.0) | 15 (12–17) | SOF+LDV; OBV/PTV/R ± DSV ± RBV | 12;24 | 38 | SVR12, 100.0 (38/38) |
| El-Shabrawi et al. (37) | Single-arm, multicenter | Egypt G4 (20) | 17/3 | 11 (55.0) | 9.1 (6–12) | SOF+LDV | 12 | 20 | SVR12, 95.0 (19/20) |
| El-Shabrawi et al. (38) | Open-label | USA NA | 9/1 | 5 (50.0) | 15.5 (13–17) | SOF+DCV | 8 | 10 | SVR12, 100.0 (10/10) |
| El-Khayat et al. (12) | Multicenter, open-label | Egypt G4 (144) | 128/16 | 99 (69.0) | 14 (12–17) | SOF+LDV | 12 | 144 | SVR12, 98.6 (144/144) |
| Wirth et al. (39) | Multicenter, open-label | USA G2 (13), G3 (39) | 43/9 | 31 (60.0) | 15 (12–17) | SOF+RBV | 12;24 | 52 | SVR12, 98.1 (52/52) |

(Continued)
of 24-week treatment. The SVR12 rates were 100% (41/41, 95% CI: 95.9–100), 98.8% (410/421, 95% CI: 97.1–99.8), and 100% (3/3, 95% CI: 50.0–100) for patients treated for 8, 12, and 24 weeks, respectively. Thus, DAAs are effective and safe in adolescents with hepatitis C (8, 49), it is unclear whether a shorter 8-week treatment cycle would achieve similar outcomes as the 12-week or even 24-week cycles. To this end, we systematically analyzed the studies published so far on the therapeutic efficacy of DAA-containing regimens in children and adolescents with HCV infection.

Prior to the regulatory approval of DAAs for pediatric patient, the standard treatment for adolescents and children infected with HCV was 24 weeks of pegIFN and RBV for GT 2 and 3, and 48 weeks for GT 1 and 4 (50–58). This combination resulted in an SVR of around 52% in patients infected with HCV GT 1 and 4, and 89% in those infected with HCV GT 2 and 3, but was associated with significant side effects (54–56, 58). Compared to IFN-based regimens, DAAs not only are more efficient but also have fewer side effects (10–12, 15–17, 22, 24–26, 28, 29, 31, 34–39). We found that the overall SVR12 rate for the adolescents and children treated with DAAs was 99.4 and 98.9%, respectively, although the frequency of AEs was substantial (34.7 and 51.6%). Nevertheless, SAEs were rare (0.2 and 1.1%) and no adolescent patients discontinued treatment due to the AEs since most were tolerable, such as headaches (22.6%), abdominal pain (21.1%), and fatigue (15.5%). Moreover, children were more likely to experience side effects compared to teenagers (51.6 vs. 34.7%). The most common AE among children was fatigue (28.4%), most likely due to “abnormal drug taste” (24, 26). Thus, DAAs are relatively well-tolerated by both children and adolescents.

### DISCUSSION

Compared to adult patients, there are significant gaps regarding the data of adolescents and children with HCV infection. Although several DAAs are effective and safe in adolescents with hepatitis C (8, 49), it is unclear whether a shorter 8-week treatment cycle would achieve similar outcomes as the 12-week or even 24-week cycles. To this end, we systematically analyzed the studies published so far on the therapeutic efficacy of DAA-containing regimens in children and adolescents with HCV infection.

Prior to the regulatory approval of DAAs for pediatric patient, the standard treatment for adolescents and children infected with HCV was 24 weeks of pegIFN and RBV for GT 2 and 3, and 48 weeks for GT 1 and 4 (50–58). This combination resulted in an SVR of around 52% in patients infected with HCV GT 1 and 4, and 89% in those infected with HCV GT 2 and 3, but was associated with significant side effects (54–56, 58). Compared to IFN-based regimens, DAAs not only are more efficient but also have fewer side effects (10–12, 15–17, 22, 24–26, 28, 29, 31, 34–39). We found that the overall SVR12 rate for the adolescents and children treated with DAAs was 99.4 and 98.9%, respectively, although the frequency of AEs was substantial (34.7 and 51.6%). Nevertheless, SAEs were rare (0.2 and 1.1%) and no adolescent patients discontinued treatment due to the AEs since most were tolerable, such as headaches (22.6%), abdominal pain (21.1%), and fatigue (15.5%). Moreover, children were more likely to experience side effects compared to teenagers (51.6 vs. 34.7%). The most common AE among children was fatigue (28.4%), most likely due to “abnormal drug taste” (24, 26). Thus, DAAs are relatively well-tolerated by both children and adolescents.
(60), Latt et al. (61), and Kattakuzhy et al. (62) analyzed the outcomes of HCV treatment shorter than 12 weeks and reported ambiguous results. A recent review has shown that 8 weeks of glecaprevir/pibrentasvir (G/P) is equally effective in treatment-naive non-cirrhotic adults (63). We did not detect any significant differences between the various treatment durations

### Figure 2: Overall rate of SVR12 in patients treated by DAAs

#### A: Patients aged 12–17 years old.

| Study                | SVR Total | Proportion   | 95%-CI | Weight |
|----------------------|-----------|--------------|--------|--------|
| Maureen M 2020       | 44/44     | 1.00         | [0.920; 1.000] | 3.5%   |
| Nahed A 2020         | 50/50     | 1.00         | [0.929; 1.000] | 4.0%   |
| Aabha 2019           | 16/18     | 0.889        | [0.663; 0.986] | 1.5%   |
| Radha K 2019         | 56/57     | 0.982        | [0.906; 1.000] | 4.5%   |
| Tawhida Y 2019       | 39/40     | 0.975        | [0.868; 0.999] | 3.2%   |
| Hanan 2019           | 51/51     | 1.00         | [0.930; 1.000] | 4.1%   |
| Hesham 2019          | 154/157   | 0.981        | [0.945; 0.996] | 12.5%  |
| Hanaa 2018           | 40/40     | 1.00         | [0.912; 1.000] | 3.2%   |
| Mostafa 2018         | 29/30     | 0.967        | [0.828; 0.999] | 2.4%   |
| Daniel H 2018        | 38/38     | 1.00         | [0.907; 1.000] | 3.0%   |
| Mortada H 2018       | 10/10     | 1.00         | [0.692; 1.000] | 0.8%   |
| Khayat 2018          | 142/144   | 0.986        | [0.951; 0.998] | 11.4%  |
| Stefan 2017          | 51/52     | 0.981        | [0.897; 1.000] | 4.2%   |
| Willian F 2017       | 98/100    | 0.980        | [0.930; 0.998] | 7.9%   |
| Mehta 2018           | 10/10     | 1.00         | [0.962; 1.000] | 0.8%   |
| Hanan M 2020         | 46/46     | 1.00         | [0.923; 1.000] | 3.7%   |
| Daniele 2019         | 14/14     | 1.00         | [0.768; 1.000] | 1.1%   |
| Serranti 2021        | 77/78     | 0.987        | [0.931; 1.000] | 6.2%   |
| Mohamed 2019         | 40/40     | 1.00         | [0.912; 1.000] | 3.2%   |
| M. El-Sayed 2017     | 13/13     | 1.00         | [0.753; 1.000] | 1.1%   |
| M.H. El-Sayed 2018   | 13/13     | 1.00         | [0.753; 1.000] | 1.1%   |
| Manal 2019           | 53/53     | 1.00         | [0.933; 1.000] | 4.2%   |
| Maureen 2020         | 97/102    | 0.951        | [0.889; 0.984] | 8.1%   |
| Sheha 2018           | 53/53     | 1.00         | [0.933; 1.000] | 4.2%   |

**Fixed effect model** 1253

- Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 0.83$
- Proportion: 0.994 [0.987; 0.999]
- Weight: 100.0%

#### B: Patients below 12 years old.

| Study            | SVR Total | Proportion   | 95%-CI | Weight |
|------------------|-----------|--------------|--------|--------|
| Philip R 2020    | 25/26     | 0.962        | [0.804; 0.999] | 5.6% |
| Behairy E 2020   | 30/30     | 1.00         | [0.884; 1.000] | 6.5% |
| Philip R 2020    | 53/54     | 0.981        | [0.901; 1.000] | 11.6% |
| Kathleen B 2020  | 33/34     | 0.971        | [0.847; 0.999] | 7.3% |
| Enas M 2020      | 22/22     | 1.00         | [0.846; 1.000] | 4.8% |
| Hanaa A2019      | 100/100   | 1.00         | [0.964; 1.000] | 21.4% |
| Shivadatta 2018  | 14/14     | 1.00         | [0.768; 1.000] | 3.1% |
| Karen F 2018     | 91/92     | 0.989        | [0.941; 1.000] | 19.7% |
| Shabrawi 2018    | 19/20     | 0.950        | [0.751; 0.998] | 4.4% |
| Maureen 2020     | 67/73     | 0.918        | [0.830; 0.969] | 15.6% |

**Fixed effect model** 465

- Heterogeneity: $I^2 = 35\%$, $\tau^2 = 0.0030$, $p = 0.13$
- Proportion: 0.989 [0.973; 0.998]
- Weight: 100.0%
in terms of efficacy in adolescents or children ($P_b = 0.398$, $P_d = 0.716$). Hesham et al. also found that 8 weeks of treatment with the SOF/LDV combination was as effective and safe as the 12-week regimen in adolescent GT 4 patients (15). Similar results were reported by Mortada et al. (38). As for the treatment cycle of 24 weeks, most just appeared in RBV-based regimen in children, because SOF+RBV was also a suboptimal regimen for persons with GT 3 infection, especially if they have liver cirrhosis (8). We found that both 8-week and 12/24-week treatment courses were well-tolerated in adolescents (31 vs. 36.1%/41.7%, $P = 0.918$), whereas the AE rate at 24 weeks was greater than that at 8/12 weeks (98.7 vs. 57.8%/45.1%, $P < 0.001$) in children with CHC. This can be attributed to RBV intolerance, as well as the fact that a longer treatment duration would also increase the chances of detecting AEs that manifest late. The correlation between treatment duration and AEs needs to be studied further.

Given the underdeveloped immune system of children and the limited time for which DAAs have been administered to

---

**TABLE 2** | Rate of SVR12 after different durations of treatment in children and adolescents.

| Subgroups     | Adolescents group (12–17 years) | Children group (<12 years) |
|---------------|---------------------------------|-----------------------------|
| Studies (n)   | SVR12 ($N = 831$)               | Heterogeneity $P_b$         |
| Total, n/N    | Rate% (95% CI)                  | $I^2$ (%)                   |
| 8 weeks       | 5 193/194 100.0 (98.7–100.0)    | 0.092                       |
| 12 weeks      | 20 998/1,015 99.3 (98.4–99.9)   | 0.78                        |
| 24 weeks      | 4 43/44 100.0 (98.9–100.0)      | 0.93                        |

| Subgroups     | Adolescents group (12–17 years) | Children group (<12 years) |
|---------------|---------------------------------|-----------------------------|
| Studies (n)   | SVR12 ($N = 392$)               | Heterogeneity $P_d$         |
| Total, n/N    | Rate% (95% CI)                  | $I^2$ (%)                   |
| 8 weeks       | 2 41/41 100.0 (95.9–100.0)      | 0.75                        |
| 12 weeks      | 9 410/421 98.8 (97.1–99.8)      | 0.11                        |
| 24 weeks      | 1 3/3 100.0 (50.0–100.0)        | NA                          |

SVR, sustained virological response; CI, confidence interval; $I^2$, I-square; NA, not applicable. $^a$ Test of heterogeneity in adolescents group; $^b$ Test for subgroup differences in adolescents group; $^c$ Test of heterogeneity in children group; $^d$ Test for subgroup differences in children group.

**TABLE 3** | AEs after different treatment durations in children and adolescents.

| Variables             | Adolescents group (12–17 years) | Children group (<12 years) |
|-----------------------|---------------------------------|-----------------------------|
| Durations of treatment| Total, n/N                      | Rate% (95% CI)              |
| 8 weeks               | 5 55/194 31.0 (0–79.2)          | 98.0 <.001                  |
| 12 weeks              | 17 297/871 36.1 (23.3–49.9)     | 94.0 <.001                  |
| 24 weeks              | 4 31/44 41.7 (94.2)             | 63.0 0.05                   |

| Durations of treatment| Total, n/N                      | Rate% (95% CI)              |
| 8 weeks               | 2 29/41 57.8 (0–100.0)          | 95.0 <.001                  |
| 12 weeks              | 8 174/385 45.1 (24.4–66.8)      | 94.0 <.001                  |
| 24 weeks              | 2 37/39 98.7 (88.9–100.0)       | 0 1.00                     |

AE, adverse event. $^a$ Test of heterogeneity in adolescents group; $^b$ Test for subgroup differences in adolescents group; $^c$ Test of heterogeneity in children group; $^d$ Test for subgroup differences in children group.

**TABLE 4** | Rate of AEs, SAEs, discontinuation, and the common AEs among children and adolescents.

| Response                  | Adolescents group (12–17 years) | Children group (<12 years) |
|---------------------------|---------------------------------|-----------------------------|
| Total AEs (not including SAEs) | 385/1,109 34.7 (31.9–37.6) | 240/465 51.6 (47.0–56.2) |
| SAEs                      | 2/1,122 0.2 (0–0.6)             | 5/465 1.1 (0.4–2.5)        |
| AEs leading to discontinuation | 0/1,253 0 (0–0.3)   | 2/465 0.4 (0.1–1.5)       |
| Headache                  | 206/910 22.6 (20.0–25.5)        | 82/297 27.6 (22.6–33.1)    |
| Fatigue                   | 129/832 15.5 (13.1–18.1)        | 80/282 28.4 (23.2–34.0)    |
| Diarrhea                  | 104/695 15.0 (12.4–17.8)        | –                          |
| Abdominal pain            | 118/560 21.1 (17.8–24.7)        | –                          |
| Nausea                    | 90/585 15.4 (12.6–18.6)         | –                          |
| Vomiting                  | –                               | 51/242 21.1 (16.1–26.8)    |
| Cough                     | –                               | 35/228 15.4 (10.9–20.7)    |
| Fever                     | –                               | 34/228 14.9 (10.6–20.2)    |

AE, adverse event; SAE, severe adverse event.
this group, our findings should be interpreted with caution. In addition, we only evaluated the efficacy of DAAs in terms of SVR12, and some subgroups did not have a corresponding control due to ethical reasons. Secondly, stratified analysis of SVR showed that the heterogeneity within the three treatment cycles was somewhat large, but the inter-group heterogeneity was not statistically significant. Lastly, only the FDA-approved DAAs were analyzed in the review. Therefore, the treatment outcomes of novel DAAs will have to be continuously monitored in children.

In conclusion, DAAs are overall effective and well-tolerated in adolescents and children with chronic hepatitis C. The 8-week treatment course is as effective as 12/24 weeks in both adolescents and children.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

**AUTHOR CONTRIBUTIONS**

ZF and MY: study design and protocol, searches, title, abstract, full-text screening, data abstraction, statistical analyses, interpretation of the data, and drafting the article. ZG and CW: data verification and statistical analyses. CS and YW: statistical analyses and interpretation of the data. PH, CD, and YZ: study design and protocol, interpretation of the data, and drafting the article. ZF, CD, PH, and MY: manuscript revision and question answer. All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was supported by the National Natural Science Foundation of China (81703273 and 81773499), the Natural Science Foundation of Jiangsu Province of China (BK20171054), the Science Foundation for Distinguished Young Scholars of Jiangsu Province (BK20190106), Jiangsu Program for Young Medical Talents (QNRC2016616), and the Key Project of Yunnan Province Applied Basic Research Program (2019FA005).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2021.608760/full#supplementary-material

**REFERENCES**

1. Spearman CW, Dunheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet. (2019) 394:1451–66. doi: 10.1016/S0140-6736(19)32320-7
2. WHO. Global Hepatitis Report. Geneva World Health Organization (2018).
3. El-Sayed MH, Razavi H. Global estimate of HCV infection in the pediatric and adolescent population. *J Hepatol.* (2015) 62:S831–2. doi: 10.1016/S0168-8278(15)31458-6
4. Bortolotti F, Verucchi G, Camma C, Cabibbo G, Zancan L, Indolfi G, et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. *Gastroenterology.* (2008) 134:1900–7. doi: 10.1053/j.gastro.2008.02.082
5. Network. The European Paediatric Hepatitis C Virus Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. *Clin Infect Dis.* (2005) 41:45–51. doi: 10.1086/430601
6. Resti M, Jara P, Hierro L, Azzari C, Giachinno R, Zuin G, et al. Clinical features and progression of perinatally acquired hepatitis C virus infection. *J Med Virol.* (2003) 70:373–7. doi: 10.1002/jmv.10405
7. Modin L, Arshad A, Wilkes B, Benselin J, Lloyd C, Irving WL, et al. Epidemiology and natural history of hepatitis C virus infection among children and young people. *J Hepatol.* (2019) 70:371–8. doi: 10.1016/j.jhep.2018.11.013
8. World Health Organisation. Guidelines for the Care and Treatment of Persons Diagnosed With Chronic Hepatitis C Virus Infection. Geneva: World Health Organisation (2018).
9. Thorne C, Indolfi G, Turkova A, Giaquinto C, Nastouli E. Treating hepatitis C in children: time for a new paradigm. *J Viral Erad.* (2015) 1:203–5. doi: 10.1016/S2055-6640(20)30000-8
10. Padhi S, Maharshi S, Gupta GK, Garg KS. Nihawan efficacy and safety of direct acting antiviral therapy for chronic hepatitis C in thalassemic children. *J Pediatr Hematol Oncol.* (2018) 40:511–4. doi: 10.1097/MPH.0000000000001217
11. El-Araby HA, Behairy BE, El-Guindi MA, Adawy NM, Allam AA, Sira AM, et al. Generic sofosbuvir/ledipasvir for the treatment of genotype 4 chronic hepatitis C in Egyptian children (9–12 years) and adolescents. *Hepatol Int.* (2019) 33:766–75. doi: 10.1007/s12072-019-09985-w
12. El-Khayat HR, Kamal EM, El-Sayed MH, El-Shabrawi M, Ayoub H, Riz KA, et al. The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience. *Aliment Pharmacol Ther.* (2018) 47:838–44. doi: 10.1111/apt.14502
13. Behairy BE, El-Araby HA, El-Guindi MA, Basiony HM, Fouad OA, Ayoub BA, et al. Safety and EFFICACY of 8 weeks Ledipasvir/Sofosbuvir for chronic hepatitis C genotype 4 in children aged 4–10 years. *J Pediatr.* (2020) 219:106–10. doi: 10.1016/j.jpeds.2019.12.034
14. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med.* (2009) 151:264–9. doi: 10.7326/0003-4819-151-4-200908180-00135
15. El-Khayat H, Kamal EM, Yakoot M, Gawad MA, Kamal N, El Shabrawi M, et al. Effectiveness of 8-week sofosbuvir/ledipasvir in the adolescent chronic hepatitis C-infected patients. *Eur J Gastroenterol Hepatol.* (2019) 31:1004–9. doi: 10.1097/MEG.0000000000001360
16. Balkrister WF, Murray KF, Rosenthal P, Bansal S, Lin CH, Kersey K, et al. The safety and effectiveness of ledipasvir/sofosbuvir in adolescents 12–17 years old with hepatitis C virus genotype 1 infection. *Hepatology.* (2017) 66:371–8. doi: 10.1002/hep.28995
17. Murray KF, Balkrister WF, Bansal S, Whitworth S, Evans HM, Gonzalez-Peralta RP, et al. Safety and efficacy of Ledipasvir-Sofosbuvir with or without ribavirin for chronic hepatitis C in children ages 6-11. *Hepatology.* (2018) 68:2158–66. doi: 10.1002/hep.30123
18. Jonas MM, Squires RH, Rhee SM, Lin CW, Bessho K, Feiterna-Sperling C, et al. Pharmacokinetics safety, and efficacy of Glecaprevir/Pibrentasvir in adolescents with chronic hepatitis C virus part 1 of the DORA study. *Hepatology.* (2020) 71:456–62. doi: 10.1002/hep.30840
19. Wang X, Fan X, Deng H, Zhang X, Zhang K, Li N, et al. Efficacy and safety of glecaprevir/pibrentasvir for chronic hepatitis C virus genotypes 1–6 infection: a systematic review and meta-analysis. *Int J Antimicrob Agents.* (2019) 54:780–9. doi: 10.1016/j.ijantimicag.2019.07.005
20. Miller John J. The inverse of the freedom – Tukey double arc sine transformation. *Am Statist.* (1978) 32:138. doi: 10.1080/00031305.1978.10479283

21. Rosenthal P, Narkezic WR, Yao BB, Jolley CD, Lobritto SJ, Wen J, et al. Ombitasvir, paritaprevir, ritonavir, and dasabuvir mini-tabs plus ribavirin for children aged 3-11 years with hepatitis C genotype 1a. *Adv Ther.* (2020) 37:3299–310. doi: 10.1007/s12325-020-01389-9

22. Fouad HM, Ahmed Mohamed A, Sabry M, Abdel Aziz H, Eysa B, Rabaa M. The effectiveness of Ledipasvir/Sofosbuvir in youth with genotype 4 hepatitis C virus: a single egyptian center study. *Pediatr Infect Dis J.* (2019) 38:22–5. doi: 10.1097/INF.0000000000002189

23. Makhlofi NA, Abdelmalek MO, Ibrahim ME, Abu-Faddan NH, Khelia AE, Mahmoud AA. Ledipasvir/Sofosbuvir in adolescents with chronic hepatitis C genotype with and without hematological disorders: virological efficacy and impact on liver stiffness. *J Pediatric Infect Dis Soc.* (2020) 4:7–13. doi: 10.1093/jpids/piaa006

24. Schwarz KB, Rosenthal P, Murray KF, Honegger JR, Hardikar W, Hague R, et al. Direct-acting antiviral therapy is safe and effective in chronic hepatitis C infection. *J Hepatol.* (2019) 71:422–30. doi: 10.1016/j.jhep.2018.06.046

25. Kamal EM, El-Shabrawi M, El-Khayat H, Yakoot M, Sameh Y, Fouad Y, et al. Ombitasvir/Paritaprevir/Ritonavir and dasabuvir with or without ribavirin for children aged 3-6 years of age with chronic hepatitis C. *Egyptian Pediatrics Journal* (2017) 41:111–4. doi: 10.1097/INF.0b013e31802dd2f6

26. El-Karaksy H, Mogahed EA, Abdullatif H, Ghobrial C, El-Raziky MS, et al. Sustained viral response in genotype 4 chronic hepatitis C virus-infected children and adolescents treated with Sofosbuvir/Ledipasvir. *J Pediatr Gastroenterol Nutr.* (2018) 67:626–30. doi: 10.1097/MPG.0000000000002101

27. El-Shabrawi MHF, Kamal NM, El-Khayat HR, Kamal EM, AbdElgawad M. A pilot single arm observational study of sofosbuvir/ledipasvir (200 + 45 mg) in 6- to 12-year-old children. *Aliment Pharmacol Ther.* (2018) 47:1699–704. doi: 10.1111/apt.14677

28. El-Shabrawi MH, Abd El-Am, El-Khayat HR, Yakoot M. Shortened 8 weeks course of dual Sofosbuvir/Dasabuvir therapy in adolescent patients, with chronic hepatitis C infection. *J Pediatr Gastroenterol Nutr.* (2016) 66:425–7. doi: 10.1097/MPG.0000000000001838

29. Wirth S, Rosenthal P, Gonzalez-Peralta RP, Jonas MM, Balisteri WF, Lin CH, et al. Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection. *Hepatology.* (2017) 66:1102–10. doi: 10.1002/hep.29278

30. Fouad HM, Ahmed Mohamed A, Sabry M, Abdel Aziz H, Eysa B, Rabaa M. The effectiveness of Ledipasvir/Sofosbuvir in youth with genotype 4 hepatitis C virus: a single egyptian center study. *Pediatr Infect Dis J.* (2019) 38:22–5. doi: 10.1097/INF.0000000000002189

31. Fu et al. Adolescents and Children With CHC

32. Kamal EM, El-Shabrawi M, El-Khayat H, Yakoot M, Sameh Y, Fouad Y, et al. Effects of sofosbuvir/ledipasvir therapy on chronic hepatitis C virus genotype 4, infected children of 3-6 years of age. *Liver Int.* (2019) 40:319–23. doi: 10.1111/j.2040-7766.2019.00449.x

33. Schwarz KB, Rosenthal P, Gonzalez-Peralta RP, Lin CH, Kelly DA, Nightingale S, et al. Ribavirin therapy for children aged 3 to <12 years with hepatitis C virus genotype 2 or 3 infection. *Hepatology.* (2019) 71:31–43. doi: 10.1002/hep.30821

34. El-Karaksy H, Mogahed EA, Abdullatif H, Ghobrial C, El-Raziky MS, et al. Sustained viral response in genotype 4 chronic hepatitis C virus-infected children and adolescents treated with Sofosbuvir/Ledipasvir. *J Pediatr Gastroenterol Nutr.* (2018) 67:86–9. doi: 10.1097/MPG.0000000000001968

35. Yakoot M, El-Shabrawi MH, AbdElgawad MM, Mahfouz AA, Helmy S, Abdo AM, et al. Dual Sofosbuvir/Dasabuvir therapy in adolescent patients with chronic hepatitis C infection. *J Pediatr Gastroenterol Nutr.* (2018) 67:86–9. doi: 10.1097/MPG.0000000000001968

36. Leung DH, Wirth S, Yao BB, Viani RM, Gonzalez-Peralta RP, Jonas MM, et al. Ombitasvir/Paritaprevir/Ritonavir with or without dasabuvir and with or without ribavirin for adolescents with HCV genotype 1 or 4. *Hepatol Commun.* (2018) 2:1311–9. doi: 10.1002/hep4.1250

37. El-Shabrawi MH, Kamal NM, El-Khayat HR, Kamal EM, AbdElgawad M. A pilot single arm observational study of sofosbuvir/ledipasvir (200 + 45 mg) in 6- to 12-year-old children. *Aliment Pharmacol Ther.* (2018) 47:1699–704. doi: 10.1111/apt.14677
54. Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. *J Hepatol*. (2010) 52:501–7. doi: 10.1016/j.jhep.2010.01.016

55. Mack CL, Gonzalez-Peralta RP, Gupta N, Leung D, Narkewicz MR, Roberts EA, et al. NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents. *J Pediatr Gastroenterol Nutr*. (2012) 54:838–55. doi: 10.1097/MPG.0b013e318258328d

56. Druiys E, Thorlund K, Wu P, Kansters S, Yaya S, Cooper CL, et al. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. *Clin Infect Dis*. (2013) 56:961–7. doi: 10.1093/cid/cis1031

57. Indolfi G, Nebbia G, Cananzi M, Maccabruni A, Zaramella M, D’Antiga L, et al. Kinetic of virologic response to pegylated interferon ribavirin in children with chronic hepatitis C predicts the effect of treatment. *Pediatr Infect Dis J*. (2016) 35:1300–3. doi: 10.1097/INF.0000000000001325

58. Wirth S, Pieper-Boustani H, Lang T, Ballauff A, Kullmer U, Gerner P, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. *Hepatology*. (2005) 41:1013–8. doi: 10.1002/hep.20661

59. Rosenthal ES, Graham CS. Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States. *Infect Agent Cancer*. (2016) 11:24. doi: 10.1186/s13027-016-0071-z

60. Kohli A, Kattakuzhy S, Sidharthan S, Nelson A, McLaughlin M, Seamon C, et al. Four-week direct-acting antiviral regimens in noncirrhotic patients with hepatitis C virus genotype 1 infection: an open-label, nonrandomized trial. *Ann Intern Med*. (2015) 163:899–907. doi: 10.7326/M15-0642

61. Latt NL, Yanny BT, Gharibian D, Gevorkyan R, Sahota AK. Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: single center, real world effectiveness and safety. *World J Gastroenterol*. (2017) 23:4759–66. doi: 10.3748/wjg.v23.i26.4759

62. Kattakuzhy S, Wilson E, Sidharthan S, Sims Z, McLaughlin M, Price A, et al. Moderate sustained virologic response rates with 6-week combination directly acting anti-hepatitis C virus therapy in patients with advanced liver disease. *Clin Infect Dis*. (2016) 62:440–7. doi: 10.1093/cid/civ897

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Fu, Dong, Ge, Wang, Zhang, Shen, Li, Zhu, Wang, Huang and Yue. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.